Is WST a good stock to buy?
West Pharmaceutical Services, Inc. · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 16
- MAs4 of 4
- Sector▲ +15.9%
- Earnings in90d
- P/E46.7x
- RSI66
- Support-12.7%
- Off 52w high-5.0%
- Volume0.6x
- Bollingerupper half
- News0.00
- FCF yield+1.6%
- Trendsideways
- 52w range$224–$438
- ATR+2.5%
- Off ATH-12.4%
- PT$413.38 -0.7%
- P/E vs own+15.8%
- P/E vs sector+45.1%
- Insiders-$3.52M
- MACD-0.08
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is West Pharmaceutical Services a good stock to buy?
West Pharmaceutical Services is strong on 2 of the 5 questions about the business; weak on advantage. The price is about usual: 46.7 times its earnings, near its 3-year median of 43.1 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage easy to copy
- Economics profits steady
- Execution delivers
- Fragility sturdy
- Price about usual
WST sales growth revenue growth
+2%a year, for the last 3 yearsWest Pharmaceutical Services' sales grew 2% a year for 3 years, to $3.07B in fiscal 2025.
WST analysts' forecast revenue estimates
+11%the sales they expect next fiscal year, on the lastAnalysts expect West Pharmaceutical Services' sales to grow 11% to $3.42B in fiscal 2026 (12 analysts).
WST competitors
pretickt analysis+13%its sales in 12 months, on a year before
West Pharmaceutical Services' sales grew 13% in the 12 months to Sep 30, 2026, faster than ResMed (+9%), Baxter (+5%), Solventum (-3%) and Becton Dickinson (-7%).
WST sales by business revenue by segment
81%of its sales from Proprietary ProductsProprietary Products brought West Pharmaceutical Services 81% of its sales in fiscal 2025; Contract Manufactured Products 19%.
WST margin on each sale gross margin
38%left after making the productWest Pharmaceutical Services kept 38% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 51%.
WST cash generated free cash flow
$453Mcash left after investing, last 12 monthsWest Pharmaceutical Services generated $453M of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.
WST earnings vs estimates
8 of 8quarters above the analysts' estimateWest Pharmaceutical Services beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 29, 2026.
WST insider selling
-$4.65Msold, net, by its executives in 12 monthsWest Pharmaceutical Services' executives and directors sold a net $4.65M of shares in the 12 months to Nov 13, 2026; none bought.
WST number of employees
+2%more people in a yearWest Pharmaceutical Services had 10,800 employees at the end of fiscal 2025, 2% more than a year before.
WST CEO pay
$7.19Mfor fiscal 2025, 62% of it in stock and optionsWest Pharmaceutical Services paid its CEO $7.19M for fiscal 2025, 62% of it in stock and options.
WST financial health Altman Z-score
19.4Altman Z-score, safe above 3West Pharmaceutical Services' Altman Z-score is 19.4 (Nov 13, 2026), above 3, where the safe zone starts.
WST quality checks Piotroski score
7 of 9checks passedWest Pharmaceutical Services passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on long-term debt and the current ratio.
WST biggest customers
16%of sales from its biggest customerOne customer, unnamed in West Pharmaceutical Services' 10-K, made 16% of its sales in fiscal 2025.
WST in past recessions
pretickt analysis0%its sales in the worst oneWest Pharmaceutical Services' sales did not fall in any of the last 2 US recessions (2008–09 and 2020).
WST price vs profit P/E ratio
46.7×a year's earningsWest Pharmaceutical Services' P/E ratio is 46.7 (Nov 13, 2026), near its 3-year median of 43.1.
WST price vs competitors
pretickt analysis46.7×a year's earnings, against its competitorsInvestors pay 46.7 times West Pharmaceutical Services' earnings (Nov 13, 2026), more than for ResMed (21.9), less than for Solventum (99.0) and Becton Dickinson (52.7).
WST analysts' target price target
-1%to their average targetAnalysts' average price target for West Pharmaceutical Services is $413, 1% below the Nov 13, 2026 close of $416.42.
WST analyst ratings, 90 days
pretickt analysisMorgan Stanleyupgrade
In the 90 days to Nov 13, 2026, Morgan Stanley upgraded West Pharmaceutical Services.
WST growth priced in fair value
pretickt analysis+23%a year, for ten years, to be worth the priceAt $416.42 a share, West Pharmaceutical Services' free cash flow must grow about 23% a year for ten years to be worth the price (Nov 13, 2026).
What is West Pharmaceutical Services' P/E ratio?
West Pharmaceutical Services' P/E ratio is 46.7 (Nov 13, 2026), near its 3-year median of 43.1. Investors pay 46.7 times West Pharmaceutical Services' earnings (Nov 13, 2026), more than for ResMed (21.9), less than for Solventum (99.0) and Becton Dickinson (52.7).
Who are West Pharmaceutical Services' biggest competitors?
pretickt compares West Pharmaceutical Services with ResMed, Solventum, Becton Dickinson and Baxter. West Pharmaceutical Services' sales grew 13% in the 12 months to Sep 30, 2026, faster than ResMed (+9%), Baxter (+5%), Solventum (-3%) and Becton Dickinson (-7%).
Are insiders selling West Pharmaceutical Services stock?
West Pharmaceutical Services' executives and directors sold a net $4.65M of shares in the 12 months to Nov 13, 2026; none bought.
How does West Pharmaceutical Services make money?
Proprietary Products brought West Pharmaceutical Services 81% of its sales in fiscal 2025; Contract Manufactured Products 19%.
How many employees does West Pharmaceutical Services have?
West Pharmaceutical Services had 10,800 employees at the end of fiscal 2025, 2% more than a year before.
Who are West Pharmaceutical Services' biggest customers?
One customer, unnamed in West Pharmaceutical Services' 10-K, made 16% of its sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.